Nektar Therapeutics Shares Surge on Eczema Drug Success
TL;DR Summary
Nektar Therapeutics' stock surged over 90% after successful midstage trial results for its eczema drug rezpegaldesleukin, which showed significant symptom improvement and demonstrated a new biological approach to treating inflammatory and autoimmune skin conditions.
- Small Biotech Launches After Hitting An Eczema Grand Slam Investor's Business Daily
- Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results Investopedia
- Investors sweet on Nektar as phase 2b eczema success doubles share price Fierce Biotech
- Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 Yahoo Finance
- Stocks to Watch: Nektar Therapeutics, Alset MarketWatch
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
90%
329 → 34 words
Want the full story? Read the original article
Read on Investor's Business Daily